The Bladder Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Bladder Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bladder Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bladder Carcinoma and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Bladder Carcinoma by 15 companies/universities/institutes. The top development phase for Bladder Carcinoma is phase ii with six drugs in that stage. The Bladder Carcinoma pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bladder Carcinoma pipeline products market are: Immatics, KaliVir Immunotherapeutics and Pan Cancer T.
The key targets in the Bladder Carcinoma pipeline products market include Tubulin, Melanoma Antigen Preferentially Expressed In Tumors, and Interleukin 12.
The key mechanisms of action in the Bladder Carcinoma pipeline product include Tubulin Inhibitor with three drugs in Phase III. The Bladder Carcinoma pipeline products include six routes of administration with the top ROA being Intravenous and seven key molecule types in the Bladder Carcinoma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Bladder Carcinoma overview
Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.Bladder cancer characteristically causes blood in the urine, which may be visible or detectable only by microscope. The best diagnosis of the state of the bladder is by way of cystoscopy.
For a complete picture of Bladder Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
